Retinoic acid therapy resistance progresses from unilineage to bilineage in HL-60 leukemic blasts

• Published in: PloS one Vol. 9; no. 6; p. e98929
• Main Authors: Jensen, Holly A, Bunaciu, Rodica P, Ibabao, Christopher N, Myers, Rebecca, Varner, Jeffrey D, Yen, Andrew
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 12.06.2014; Public Library of Science (PLoS)
• Subjects: Aberration; Acid resistance; Acids; Acute myeloid leukemia; Acute promyeloid leukemia; Analysis; Antigens, CD - genetics; Antigens, CD - metabolism; Antineoplastic Agents - pharmacology; Biology and Life Sciences; Biotechnology; Blast resistance; Breast cancer; Calcitriol; CD11b antigen; CD14 antigen; CD38 antigen; Cell cycle; Cell Differentiation; Cell division; Cell Line, Tumor; Chemical compounds; Cluster analysis; Clustering; Cytometry; Defects; Differentiation; Flow cytometry; G1 Phase Cell Cycle Checkpoints; Granulocyte Precursor Cells - cytology; Granulocyte Precursor Cells - drug effects; Granulocyte Precursor Cells - metabolism; Health aspects; Humans; Induction therapy; Kinases; Leukemia; Ligands; Maturation; Medicine and Health Sciences; Metabolism; Monocytes; Mutation; Patients; Pharmacology; Phosphorylation; Raf protein; Research and Analysis Methods; Retinoic acid; Rodents; Signaling; Therapy; Tretinoin; Tretinoin - pharmacology; Vitamin D3; New York; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0098929

Emergent resistance can be progressive and driven by global signaling aberrations. All-trans retinoic acid (RA) is the standard therapeutic agent for acute promyelocytic leukemia, but 10-20% of patients are not responsive, and initially responsive patients relapse and develop retinoic acid resistance. The patient-derived, lineage-bipotent acute myeloblastic leukemia (FAB M2) HL-60 cell line is a potent tool for characterizing differentiation-induction therapy responsiveness and resistance in t(15;17)-negative cells. Wild-type (WT) HL-60 cells undergo RA-induced granulocytic differentiation, or monocytic differentiation in response to 1,25-dihydroxyvitamin D3 (D3). Two sequentially emergent RA-resistant HL-60 cell lines, R38+ and R38-, distinguishable by RA-inducible CD38 expression, do not arrest in G1/G0 and fail to upregulate CD11b and the myeloid-associated signaling factors Vav1, c-Cbl, Lyn, Fgr, and c-Raf after RA treatment. Here, we show that the R38+ and R38- HL-60 cell lines display a progressive reduced response to D3-induced differentiation therapy. Exploiting the biphasic dynamic of induced HL-60 differentiation, we examined if resistance-related defects occurred during the first 24 h (the early or "precommitment" phase) or subsequently (the late or "lineage-commitment" phase). HL-60 were treated with RA or D3 for 24 h, washed and retreated with either the same, different, or no differentiation agent. Using flow cytometry, D3 was able to induce CD38, CD11b and CD14 expression, and G1/G0 arrest when present during the lineage-commitment stage in R38+ cells, and to a lesser degree in R38- cells. Clustering analysis of cytometry and quantified Western blot data indicated that WT, R38+ and R38- HL-60 cells exhibited decreasing correlation between phenotypic markers and signaling factor expression. Thus differentiation induction therapy resistance can develop in stages, with initial partial RA resistance and moderate vitamin D3 responsiveness (unilineage maturation block), followed by bilineage maturation block and progressive signaling defects, notably the reduced expression of Vav1, Fgr, and c-Raf.